|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| HIV | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Hypersensitivity | |||||
| 3 | More general conditions related to this trial | ||||
| Immune System Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| Observational Study | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Abacavir | |||||
| 6 | More general drug interventions related to this trial | ||||
| Anti-HIV Agents | |||||
| Anti-Infective Agents | |||||
| Anti-Retroviral Agents | |||||
| Antiviral Agents | |||||
| Enzyme Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Nucleic Acid Synthesis Inhibitors | |||||
| Pharmacologic Actions | |||||
| Reverse Transcriptase Inhibitors | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| GlaxoSmithKline | |||||